# the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

> **NCT06650007** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 218 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** HRS9531 Injection
- **DRUG:** HRS9531 Placebo Injection

## Key facts

- **NCT ID:** NCT06650007
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2025-05-14
- **Final completion:** 2026-07
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650007, "the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06650007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*